论文部分内容阅读
目的探讨复方樟柳碱联合腺苷钴胺治疗缺血性视神经病变的疗效及护理。方法将60例缺血性视神经病变患者随机分成观察组(30例)和对照组(30例),观察组给予复方樟柳碱注射液(由北京紫竹药业有限公司生产)颞浅动脉旁注射联合腺苷钴胺(重庆药友有限公司生产)1.5 mg肌肉注射,对照组给予复方樟柳碱注射液颞浅动脉旁注射联合维生素B120.5 mg肌肉注射,两组均治疗1个疗程(14 d)后观察疗效。结果观察组显效18例,好转12例,无效0例;对照组显效12例,好转10例,无效8例,经t检验两组差异有统计学意义(t=4.66,P<0.05)。结论复方樟柳碱联合腺苷钴胺治疗缺血性视神经病变较常规治疗起效快,作用明显,安全有效。
Objective To investigate the efficacy and nursing of compound anisodine combined with adenosylcobalamin in the treatment of ischemic optic neuropathy. Methods Sixty patients with ischemic optic neuropathy were randomly divided into the observation group (30 cases) and the control group (30 cases). The observation group was given compound anisodine injection (produced by Beijing Zizhu Pharmaceutical Co., Ltd.) Combined with adenosylcobalamin (Chongqing Pharmaceutical Co., Ltd.) 1.5 mg intramuscular injection, the control group were given compound anisodine injection of superficial temporal artery injection combined with vitamin B120.5 mg intramuscular injection, two groups were treated with a course of treatment (14 d) after the observation effect. Results The observation group was significantly improved in 18 cases, improved in 12 cases, ineffective in 0 cases; the control group markedly effective in 12 cases, improved in 10 cases, 8 cases ineffective, the t test showed significant difference between the two groups (t = 4.66, P <0.05). Conclusion Compound anisodine combined with adenosylcobalamin treatment of ischemic optic neuropathy than the conventional treatment of rapid onset, the role of obvious, safe and effective.